EASL 2012: New Data to Show Viral Cure Rates in the Most Difficult to Treat Hepatitis C Patients

April 05, 2012 03:00 AM Eastern Daylight Time

Boehringer Ingelheim to present five abstracts at ILC^TM (EASL) including data on interferon-free treatment in genotype-1 patients and those with advanced disease

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S.A. only

Key data from Boehringer Ingelheim’s hepatitis C virus (HCV) clinical trial programme, HCVerso^TM, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities. These data are one of five abstracts from a range of new Boehringer Ingelheim HCV data that have been accepted for presentation at the International Liver Congress (ILC)^TM 2012, taking place 18^th– 22^nd April in Barcelona, Spain.

Boehringer Ingelheim’s accepted abstracts not included in EASL media activities can be accessed through the EASL website today, www.easl.eu. The Boehringer Ingelheim data included in EASL media activities will remain under embargo until the time of presentation on 21^st April. All Boehringer Ingelheim’s data presentations are listed below.

Collectively, these data underscore the company’s focus on finding answers to the challenges faced by HCV patients.

Boehringer Ingelheim is continuing to support its aim of delivering a simpler HCV cure for all patients, including those toughest to treat through the company’s rigorous clinical trial programme; HCVerso^TM.

For more information on Boehringer Ingelheim’s HCV portfolio, please visit www.boehringer-ingelheim.com and follow the company on Twitter www.twitter.com/boehringer.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Within the company’s global research network, Virology is one of the seven R&D areas with focus on Hepatitis C.

In 2010, Boehringer Ingelheim posted net sales of while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

Contacts

Boehringer Ingelheim GmbH
Julia Meyer-Kleinmann
Director Corporate Communications
Phone: + 49 - 6132 – 77 8271
Fax: + 49 - 6132 – 77 70 77
E-mail: press@boehringer-ingelheim.com

Source